AH: WILEX AG announces change on the Executive Management Board
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160602_ah_wilex_cso_eng_final.pdf
- Datum: Thursday, 02 June 2016 12:54
AH: WILEX AG secures further financing with shareholder loan based on an existing financing commitment
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20161011_ah_wilex_loan_eng_final.pdf
- Datum: Tuesday, 11 October 2016 12:50
PM: Advanced Proteome Therapeutics Corporation and WILEX subsidiary Heidelberg Pahrma collaborate to create improve cancer therapeutics
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160614_pi_hdp_apc_cooperation_engl_final.pdf
- Datum: Tuesday, 14 June 2016 12:53
PR: WILEX AG announces change on the Executive Management Board
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160602_pm_wilex_cso_eng_final.pdf
- Datum: Thursday, 02 June 2016 12:53
PR: WILEX AG plans change on Supervisory Board
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160406_pm_wilex_ar_krebs_englisch_final.pdf
- Datum: Wednesday, 06 April 2016 12:56
PR: WILEX AG successfully completes capital increase
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160414_wilex_mitteilung_q1-2016_english_final_copy_1.pdf
- Datum: Monday, 25 April 2016 12:55
PR: WILEX AG: European Patent Office grants patent for the chemical synthetic building block dihydroxyisoleucine for the production of Amanitin
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160628_pm_patent_dihydroxyisoleucin_eng_final.pdf
- Datum: Tuesday, 28 June 2016 12:52
PR: WILEX AG: Interim Management Statement on the First Nine Months of 2016
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20161013_wilex_interim-management-statement_q3-2016_engl_final.pdf
- Datum: Thursday, 13 October 2016 12:49
PR: WILEX AG: Interim management statement on the first quarter of 2016
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160414_wilex_mitteilung_q1-2016_english_final.pdf
- Datum: Thursday, 14 April 2016 12:55
PR: WILEX AG: Subsidiary Heidelberg Pharma and Nordic Nanovector Enter into Collaboration to Develop Novel Antibody Drug Conjugates (ADC)
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20161026_pm_cooperation-nordic-nanovector_eng_final.pdf
- Datum: Wednesday, 26 October 2016 12:48
PR: WILEX AG: Subsidiary Heidelberg Pharma contracts Suisse CDMO Celonic for antibody cell line development and antibody production
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160927_press-release_celonic_engl_final.pdf
- Datum: Tuesday, 27 September 2016 12:50
PR: WILEX AG: Subsidiary Heidelberg Pharma Signs Option Agreement with Max Delbrück Center
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160919_pm_lizenz-max-delbruck-zentrum_eng_final.pdf
- Datum: Monday, 19 September 2016 12:51
PR: WILEX AG: US-patent office granted patent for amatoxin conjugates for tumour therapy
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160202_pr_patent-amanitin_eng_final.pdf
- Datum: Tuesday, 02 February 2016 11:57
PR: WILEX announces financial figures for the 2015 financial year and reports on course of business
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160322_pi-fy2015_wilex_eng_final.pdf
- Datum: Tuesday, 22 March 2016 11:57
PR: WILEX publishes Half-yearly Financial Report
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160714_pi_q2-2016_englisch_final.pdf
- Datum: Thursday, 14 July 2016 12:52
PR: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON® in China
- PDF File: images/files/press-releases-and-ad-hoc-announcements/20160113_pr_link-health-ind-mesu_final.pdf
- Datum: Wednesday, 13 January 2016 11:58
AH: WILEX AG erhält Gesellschafterdarlehen im Rahmen einer bestehenden Finanzierungszusage
AH: WILEX AG gibt Veränderung im Vorstand bekannt
AH: WILEX AG plant Bezugsrechtsbarkapitalerhöhung unter Ausnutzung genehmigten Kapitals
PM: Advanced Proteome Therapeutics Corporation und WILEX’ Tochtergesellschaft Heidelberg Pharma kündigen Kollaboration zur Entwicklung verbesserter Krebstherapien an
PM: WILEX AG gibt Veränderung im Vorstand bekannt
PM: WILEX AG plant Veränderung des Aufsichtsrats
PM: WILEX AG schließt Kapitalerhöhung erfolgreich ab
PM: WILEX AG: Europäisches Patentamt erteilt Patent für den chemischen Synthesebaustein Dihydroxy-Isoleucin für die Herstellung von Amanitin
PM: WILEX AG: Tochtergesellschaft Heidelberg Pharma schließt Vertrag mit Schweizer CDMO Celonic für die Entwicklung von Antikörper-Zelllinien und Antikörperproduktion ab
PM: WILEX AG: Tochtergesellschaft Heidelberg Pharma und Max-Delbrück-Centrum unterzeichnen Optionsvertrag
PM: WILEX AG: Tochtergesellschaft Heidelberg Pharma und Nordic Nanovector kollaborieren zur Entwicklung neuer Antikörper-Wirkstoff-Konjugate (ADC)
PM: WILEX AG: US-Patentamt erteilt Patent für Amatoxin-Konjugate für die Tumortherapie
PM: WILEX AG: Zwischenmitteilung erstes Quartal 2016
PM: WILEX AG: Zwischenmitteilung für die ersten neun Monate 2016
PM: WILEX Partner Link Health reicht Protokoll für klinische Phase I mit dem uPA-Inhibitor MESUPRON® in China ein
PM: WILEX Partner Link Health reicht Protokoll für klinische Phase I mit dem uPA-Inhibitor MESUPRON® in China ein
- PDF File: images/files/annual-general-meeting/2022/20160113_pr_link-health-ind-mesu_dt_final.pdf
- Datum: 13.01.2016